文献速递神经肿瘤

COATING随机对照试验:表面修饰血流导向装置单抗治疗1个月安全性结果

1-month safety results in a randomized controlled trial (COATING) evaluating a surface-modification flow diverter (p64-MW-HPC) under single antiplatelet treatment
RSS 订阅 · Journal of NeuroInterventional Surgery

COATING是首个评估表面修饰血流导向装置p64-MW-HPC在单抗血小板治疗下安全性的随机对照试验。以术后48小时DWI病灶作为血栓栓塞事件标志物,p64-MW-HPC联合SAPT与裸金属p64-MW联合DAPT相比达到非劣效。两组在术中及术后1个月内的血栓栓塞事件无统计学显著差异。

要点

  • 表面修饰血流导向装置p64-MW-HPC联合单抗血小板治疗在48小时DWI病灶方面非劣效于裸装置联合双抗。
  • 两组术中及术后1个月血栓栓塞事件无统计学显著差异。
  • 结果为未破裂颅内动脉瘤患者采用单抗血小板治疗下使用表面修饰血流导向装置提供了安全性证据。

核心结论

  • 表面修饰血流导向装置p64-MW-HPC在单抗血小板治疗下,以48小时DWI病灶为血栓栓塞标志物,非劣效于裸金属p64-MW联合双抗血小板治疗。
  • 两组术中及术后1个月内的血栓栓塞事件无统计学显著差异。

研究设计与样本

  • COATING为随机对照试验,评估表面修饰血流导向装置p64-MW-HPC在单抗血小板治疗下的安全性,对照为裸金属p64-MW联合双抗血小板治疗。

主要发现

  • 主要终点为术后48小时DWI病灶作为血栓栓塞事件标志物,表面修饰装置联合SAPT组与裸装置联合DAPT组相比达到非劣效。
  • 术中及术后1个月内的血栓栓塞事件在两组间无统计学显著差异。

临床怎么用

  • 对于需要血流导向治疗但不适合双抗血小板治疗的颅内动脉瘤患者,表面修饰p64-MW-HPC联合单抗血小板治疗可能提供与裸装置联合双抗相似的血栓栓塞安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

WHAT IS ALREADY KNOWN ON THIS TOPIC Flow diversion is the most effective treatment for intracranial aneurysms (IAs), but its use is restricted to unruptured IAs since it requires dual antiplatelet treatment (DAPT). WHAT THIS STUDY ADDS COATING is the first randomized controlled trial evaluating a surface-modified (SM) flow diverter (FD) (p64-MW-HPC (hydrophilic polymer coating)) under single antiplatelet treatment (SAPT), showing non-inferiority in terms of diffusion-weighted imaging (DWI) lesions as a marker for thromboembolic events (TE) at 48 hours post-procedure compared with bare FD (p64-MW) under DAPT. No statistically significant difference between the study arms in terms of intra-procedural and post-procedural (up to 1 month) TE was observed. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE, OR POLICY These results confirm a similar level of safety in terms of TE in patients treated with SM p64-MW-HPC under SAPT and those treated with bare p64-MW under DAPT,...

来源:Journal of NeuroInterventional Surgery,查看原文。版权归原作者所有。

引用

  1. Journal of NeuroInterventional Surgery:1-month safety results in a randomized controlled trial (COATING) evaluating a surface-modification flow diverter (p64-MW-HPC) under single antiplatelet treatment

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。